INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management

In today’s episode, we spoke with Davide Melisi, MD, PhD. Dr Melisi is an associate professor of medical oncology at the University of Verona in Italy.

In our exclusive interview, Dr Melisi discussed the investigational oral KRAS G12D inhibitor INCB161734, its mechanism of action, what early data have shown with the agent, and the aims of the ongoing phase 3 DAWN-303 trial (NCT07522073) evaluating it in patients with KRAS G12D–mutated metastatic pancreatic ductal adenocarcinoma. He also explored how the agent could be integrated into treatment sequencing alongside the August 2026 FDA approval of daraxonrasib (Rasonque) for the treatment of patients with metastatic disease.